Kanrenol

Potassium canrenoate, the active ingredient in Kanrenol, is an aldosterone antagonist (potassium‑sparing diuretic) presented as an oral formulation for oral use. It treats hypertension, congestive heart failure and edema associated with liver or kidney disease in adult patients.

GNH USA supplies Kanrenol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanrenol acts as an aldosterone antagonist to manage conditions where fluid overload or elevated blood pressure is present.

Hypertension: helps lower systemic blood pressure by promoting sodium excretion. Congestive heart failure: reduces preload and pulmonary congestion through diuresis. Edema associated with liver or kidney disease: facilitates removal of excess fluid while preserving potassium levels.

Kanrenol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Dizziness or light‑headedness. - Headache. - Gastrointestinal discomfort such as nausea or abdominal cramps. - Fatigue or weakness. - Menstrual irregularities in women.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmias. - Acute renal failure or worsening kidney function. - Life‑threatening angioedema. - Hepatic dysfunction. - Severe electrolyte disturbances. - Anaphylactic reactions.

Before initiating Kanrenol, clinicians should assess patient-specific risk factors and monitor relevant laboratory parameters.

Monitor serum potassium: check levels regularly to avoid hyperkalemia. Assess renal function: evaluate creatinine and eGFR before and during therapy. Use caution in diabetes: monitor blood glucose as potassium shifts may affect control. Avoid in severe hepatic impairment: reduced metabolism can increase drug exposure. Adjust dose in elderly patients: start low and titrate cautiously. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Kanrenol can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use markedly raises potassium levels. - Potassium supplements or salt substitutes: increase risk of hyperkalemia. - NSAIDs: may impair renal function and potentiate potassium retention.

Moderate Interactions (Monitor Closely): - Digoxin: elevated potassium can alter digoxin toxicity. - Lithium: concurrent use may increase lithium concentrations.